Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $83,576 | $82,295 | $80,802 | $73,712 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Cost of Goods Sold | $37,096 | $35,380 | $32,522 | $32,222 |
| Gross Profit | $46,480 | $46,915 | $48,280 | $41,490 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| R&D Expenses | $0 | $5,067 | $4,710 | $6,106 |
| G&A Expenses | $0 | $0 | $0 | -$13,966 |
| SG&A Expenses | $43,823 | $34,561 | $34,496 | $35,490 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $49,456 |
| Other Operating Expenses | $0 | $46 | -$29 | $122 |
| Operating Expenses | $43,823 | $39,628 | $39,206 | $41,596 |
| Operating Income | $2,657 | $7,287 | $9,073 | -$106 |
| % Margin | 3.2% | 8.9% | 11.2% | -0.1% |
| Other Income/Exp. Net | $1,807 | -$1,363 | -$1,975 | -$296 |
| Pre-Tax Income | $4,464 | $5,924 | $7,098 | -$402 |
| Tax Expense | $1,164 | $2,238 | $1,793 | $972 |
| Net Income | $2,873 | $3,087 | $4,363 | -$1,902 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS | 35.05 | 37.66 | 53.22 | -23.2 |
| % Growth | -6.9% | -29.2% | 329.4% | – |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| Weighted Avg Shares Out | 82 | 82 | 82 | 82 |
| Weighted Avg Shares Out Dil | 82 | 82 | 82 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $743 | $718 | $555 | $434 |
| Interest Expense | $85 | $62 | $47 | $22 |
| Depreciation & Amortization | $0 | $743 | $6,952 | $6,716 |
| EBITDA | $4,549 | $6,729 | $14,097 | $6,336 |
| % Margin | 5.4% | 8.2% | 17.4% | 8.6% |